Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Trial Profile

Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2018

At a glance

  • Drugs Lenalidomide (Primary) ; Bortezomib; Bortezomib; Carfilzomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Biomarker; Therapeutic Use
  • Acronyms ENDURANCE
  • Most Recent Events

    • 26 Jan 2018 Planned number of patients changed from 756 to 1080.
    • 07 Dec 2017 Planned primary completion date changed from 1 Nov 2024 to 1 Nov 2023.
    • 13 Oct 2017 Planned primary completion date changed from 1 May 2016 to 1 Nov 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top